INTRODUCTION
Light chain deposition disease (LCDD) is a rather uncommon monoclonal gammopathy. It is a systemic disease with cardiac, hepatic, and gastrointestinal lesions, with kidney impairment that usually dominates the picture. 1, 2 The patients with renal involvement usually present with nephrotic syndrome or asymptomatic proteinuria with renal impairment, which may be rapidly progressive in some cases.
In LCDD, the light chain fragments do not form amyloid fibrils; hence they are also known as non-amyloid immunoglobulin light chains. 2 These light chains are overproduced by an abnormal clone of B cells, usually seen in plasma cell dyscrasias and lymphoproliferative disorders. The disease may occur in absence of any hematological
The light chains produced are filtered by the glomeruli and reabsorbed in the proximal tubules via receptor mediated endocytosis; hence, the kidney is a prominent target for the deposition of these light chains. 3 It is a difficult condition to diagnose because the patients may not have a known lymphoplasmacytic disorder, and in 40% of cases, there may not be one. If monoclonal light chains are present in serum and/or urine, a diagnosis is possible.
In the study by Paueksakon et al, none of the patients with LCDD had multiple myeloma, though all of them had some degree of bone marrow plasmacytosis. 4 Other lesions that occur due to deposition of monoclonal light chains include Bence-Jones cast nephropathy and amyloid 59 (light chain associated). Of these, only cast nephropathy is regularly associated with multiple myeloma. These lesions usually occur alone, but may occur in combination. 5 We take a more detailed look at all the morphological features, immunofluorescence findings, electron micrographs, and possible diagnostic pitfalls of this complicated condition.
DISCUSSION

Historical considerations
In 1845, a prominent physician in London, Dr. Thomas Watson examined a patient who presented with severe weakness, puffiness of face and ankles, and pallor. His urine was described as opaque, acidic and having high specific gravity and sent to Dr. Henry Bence Jones, a famous chemical pathologist at that time. Dr. Watson believed that the high specific gravity and opacity of urine was due to presence of an abnormal proteinaceous substance. This protein was later identified as Bence Jones protein. These proteins were proposed to be toxic by Krauss in the early 1920s. Korngold and Lipari further designated the types of Bence Jones proteins as kappa and lambda. These were found to be identical to light chains prepared from serum immunoglobulin G myeloma protein, by Edelman and Gally. 6 Heavy chain deposition disease was described in 1993 by Aucouturier et al. Though there were similarities with light chain deposition disease, it was finally recognized as a separate entity. 7 Currently, the term Monoclonal Immunoglobulin Deposition Disease is used to encompass the different deposition diseases. They include light LCDD, heavy chain deposition disease, and light chain cast nephropathy.
Biochemical findings, clinical course and therapy
Patients are typically elderly with a slight male preponderance. However, a wide range of patients ranging from 28 to 94 years were found in a relatively large study performed by Pozzi et al. 3 Most patients also have monoclonal proteins in serum and urine. Patients can present with acute renal failure, rapidly progressive renal failure or chronic renal failure. Other less common features include hypertension and hematuria. Deposition in other rarer sites includes lung, brain, skin and peripheral nerves.
Proteinuria is usually >1g/dl and occurs in 80% to 90% of patients. It is nephrotic in 28 to 53% of cases; the proteinuria is non-selective. Hematuria may also be seen in up to 30% of the cases. 7 Monoclonal light chains may appear only intermittently at low concentrations in serum and/or urine. Immunofixation and high-resolution electrophoresis are much more sensitive than traditional electrophoretic methods. 7 Up to 15% of cases may not show abnormality in immunoelectrophoresis. 8 Median survival time from diagnosis is about 18 months. Early chemotherapy may slow progression of chronic renal failure and prolong life. 9 Survival is variable, and ranges from 1 month to 10 years from the onset of symptoms. Death usually occurs due to heart or liver failure or from its progression to multiple myeloma. 2 However, there has been a report of reversal of nodular lesions and renal function after chemotherapy. 10 Renal transplantation in these patients has been seriously debated. Some suggest that the patient should be free of extra-renal manifestations in the initial presentation or for more than one year in patients on chemotherapy for plasma cell dyscrasia. These patients represents a minority of the cases. 11 Recurrence in the allograft is quite common as discovered by Leung in 5 out of 7 cases. 8 The only long term survivor was a patient who had a normal bone marrow biopsy before the transplantation. 12 Recurrence has been estimated to be more than 50% within 4 years after transplantation. Conversely, de novo LCDD rarely occurs in allografts. 13 Factors indicating poorer survival include the initial creatinine and serum calcium levels, types of immunoglobulin deposits and types of lesions seen in the renal biopsy. 
Light microscopy and differential diagnosis
Microscopically, all the different renal compartments may be affected. The glomeruli may appear unremarkable in the early part of the disease. In later cases, there may be increased mesangial matrix in the glomeruli, along with diffuse and nodular glomerulosclerosis. These nodules should be differentiated from other forms of renal disease which show nodular glomerulosclerosis, like diabetes, amyloidosis and cryoglobulinemia ( fig. 1A and B) Nodular glomerulosclerosis may be seen in 50% of cases with nephrotic range proteinuria and 25% of non-nephrotic range patients. 9 A common finding is the thickening and wrinkling of peripheral basement membranes ( fig. 2 ).
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Crescents and membranoproliferative pattern with lobular accentuation and hypercellularity may also be seen. 8 Tubules show thickening of tubular basement membranes, and there may be extensive tubular atrophy and interstitial fibrosis ( fig. 2) . Arteriolar hyalinosis may be one of the findings and there may also be concentric thickening of small and medium sized arteries. These deposits are negative for Congo Red, an important differentiating point from amyloidosis. 2, 8 LCDD usually occurs singly, without presence of any associated diseases. However, Lam and Chan reported an unusual case with there was LCDD, renal amyloidosis and cast nephropathy. 14 Other associations seen in a series of 24 cases were with cast nephropathy with light chain disease and light chain disease with amyloidosis of other organs (tongue and heart). 15 LCDD has also been known to occur in conjunction with heavy chain disease. 
Immunofluorescence findings
Immunofluorescence typically shows a monoclonal linear staining in the glomerular and tubular basement membrane, mostly for kappa ( fig. 3A) . Because light microscopy may be unremarkable, immunofluorescence is a must in order to rule out light chain disease, especially in patients with suspected disease. 3 Sometimes, the typical linear staining pattern may not be present especially when there is a small amount of deposition of light chains. In these cases, electron microscopy will be more sensitive. 16 In addition, generic antibodies to kappa and lambda light chains may not detect all light chains which may have structural differences or may be altered in presence of coexisting diabetes ( fig 3B) . They can be detected only by specific antibodies directed towards these altered light chains.
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Electron microscopy findings Electron microscopy shows nodular expansion of mesangial matrix. Granular electron dense deposits can be seen in the mesangium and renal basement membranes (fig.4) . 9 Even immunofluorescence negative cases can be diagnosed with the help of electron microscopy, which has a much higher resolution and is able to detect even small deposits. the lesions may be missed, causing discrepancy with the immunofluorescence findings.
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Either immunofluorescence or electron microscopy can be more diagnostic than the other, due to limitations of each investigation.
Ultrastructural immunolabeling may be even more helpful, and combines immunofluorescence and ultrastructure into a single diagnostic tool. This may be invaluable, especially in early and subtle lesions with light chain deposition in areas other than the mesangial nodules. 16, 17 CONCLUSION LCDD should be considered as a possibility in any patients with renal insufficiency of unknown origin. In patients with nephrotic syndrome or chronic renal failure, LCDD should be considered in the differential diagnosis, especially if there is nodular glomerulosclerosis and thickening of tubular basement membranes in the renal biopsy. The background of a lymphoplasmacytic disorder makes this diagnosis all the more likely. Repeated testing with urine and serum for light chains, bone marrow examination, and detailed renal biopsy workup along with light chain immunofluorescence and electron microscopy is required in order to diagnose this elusive disorder.
